Sign Out
Kisqali is indicated for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in patients who have received prior endocrine therapy.
In pre- or perimenopausal women, or men, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.
